Phase 1 Melanoma Trial, Recruiting NCT05620290 Sponsor: Sunnybrook Health Sciences Centre Condition: Melanoma
Back to Melanoma

Phase 1 Melanoma Trial, Recruiting

NCT05620290
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with melanoma or another type of skin cancer (confirmed by biopsy), including cases where the cancer has spread to other parts of the body
  • Your skin cancer is classified as Stage I through Stage IV according to standard cancer staging guidelines
  • You have been referred for a type of radiation therapy (such as standard radiotherapy, palliative radiotherapy, or a targeted form called SBRT or hypofractionation)
  • You are currently receiving immunotherapy treatment
  • You are able to understand and sign a consent form, and you weigh less than 140kg
  • The area of cancer being treated can be seen on a type of MRI scan that does not use contrast dye
  • The treatment area can be physically reached using the MRI-guided focused ultrasound (MRg-FU) procedure used in this trial
  • You are able to communicate what you are feeling during the treatment session
  • Your kidney function is within a normal or acceptable range (confirm with trial site)

Who may not be able to join:

  • You are pregnant or breastfeeding, or you are able to have children but are not willing to use an effective form of contraception
  • You are unable to have a contrast-enhanced MRI scan for any reason
  • The area of skin being treated has open sores, is bleeding, or has any discharge
  • You have serious long-term heart, nervous system, kidney, or blood-related conditions
  • Your general health and ability to carry out daily activities is significantly limited (rated 3 or higher on a standard medical scale), or you are unable to stay still for the duration of the treatment
  • You have a serious heart condition, including a heart attack in the past six months, unstable chest pain, heart failure, a pacemaker, irregular heart rhythm, or poor heart pumping function
  • You have a personal or family history of a specific heart rhythm problem (called QT prolongation), or you take certain medicines that can affect heart rhythm — such as some antibiotics, antidepressants, antipsychotics, or heart rhythm medications (confirm with trial site for the full list)
  • You have severely high blood pressure, with the lower number reading above 100 mmHg
  • You have a history of bleeding problems or issues with blood clotting
  • Your kidneys are severely impaired, or you are currently on dialysis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dr. Gregory Czarnota, MD, Ph.D., Sunnybrook Health Sciences Centre

Phone: (416) 480-6128

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
15 June 2022
Est. completion
11 July 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Incidence of toxicity and adverse events, scored on the National Cancer Institute Common Toxicity Criteria (NCI CTCAE 4.03)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov